RAC1 (P63000) variants and mutations
RAC1 (also known as P63000) is a human protein-coding gene encoding a ras-related C3 botulinum toxin substrate 1 protein. It acts as a molecular switch controlling actin remodeling, cell migration, membrane trafficking, reactive-oxygen production, and developmental signaling. De novo activating or loss-of-function variants can cause neurodevelopmental syndromes with abnormal brain growth and craniofacial features. This analysis covers 508 RAC1 variants and mutations. Of these, 63% have computational variant effect predictions. Disease context includes intellectual disability, autosomal dominant 48, melanoma, and cutaneous melanoma. Example RAC1 variants include Q2*, Q2E, and Q2K.
Variant analysis overview
- Gene: RAC1
- Protein: P63000
- UniProt accession: P63000
- Organism: Homo sapiens
- Variants analyzed: 508
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 400 unspecified-consequence records; 49 missense variants; 41 synonymous variants; 7 frameshift variants; 4 stop-gained variants; 1 in-frame insertions; 1 in-frame deletions; 4 splice-region variants; 1 substitution
- Prediction scores: 318 variants have prediction scores (63% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: intellectual disability, autosomal dominant 48, melanoma, cutaneous melanoma, cutaneous leishmaniasis, head and neck squamous cell carcinoma, Abnormality of the skeletal system, Global developmental delay, hereditary disease, cancer, neurodegenerative disease, neurodevelopmental disorder, Intellectual disability.
Protein structure and variant hotspots
- Protein features: 22 binding sites; 8 post-translational modification sites.
- PTM context: 14 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable RAC1 variants
Examples include Q2*, Q2E, Q2K, Q2L, Q2R, Q2P, Q2H, Q2Q. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- Q2* (p.Gln2Ter), Ensembl rs2115177159, CADD 41.00
- Q2E (p.Gln2Glu), gnomAD 7-6374739-C-G, REVEL 0.12, CADD 22.90
- Q2K (p.Gln2Lys), gnomAD 7-6374739-C-A, REVEL 0.14, CADD 23.10
- Q2L (p.Gln2Leu), gnomAD 7-6374740-A-T, REVEL 0.28, CADD 24.20
- Q2R (p.Gln2Arg), gnomAD 7-6374740-A-G, REVEL 0.16, CADD 22.70
- Q2P (p.Gln2Pro), gnomAD 7-6374740-A-C, REVEL 0.31, CADD 26.40
- Q2H (p.Gln2His), gnomAD 7-6374741-G-C, REVEL 0.18, CADD 23.60
- Q2Q (p.Gln2Gln), gnomAD 7-6374741-G-A, CADD 13.70
- A3T (p.Ala3Thr), Ensembl rs2115177161, REVEL 0.18, CADD 22.40
- A3V (p.Ala3Val), Ensembl rs2115177165, REVEL 0.22, CADD 25.00
- A3S (p.Ala3Ser), gnomAD 7-6374742-G-T, REVEL 0.15, CADD 21.20
- A3P (p.Ala3Pro), gnomAD 7-6374742-G-C, REVEL 0.31, CADD 23.10
- A3G (p.Ala3Gly), gnomAD 7-6374743-C-G, REVEL 0.12, CADD 23.80
- A3D (p.Ala3Asp), gnomAD 7-6374743-C-A, REVEL 0.32, CADD 23.90
- A3A (p.Ala3Ala), rs35917954, gnomAD 7-6374744-C-T, CADD 16.30
- I4F (p.Ile4Phe), cosmic curated COSV10064, REVEL 0.38, CADD 26.60
- I4M (p.Ile4Met), rs1322357597, ClinGen CA366756911, ClinVar RCV004526373, REVEL 0.21, CADD 24.00, Uncertain significance, not specified
- I4N (p.Ile4Asn), Ensembl rs2115177172, REVEL 0.55, CADD 28.00
- I4S (p.Ile4Ser), gnomAD 7-6374742-GC-G, CADD 27.10
- I4V (p.Ile4Val), gnomAD 7-6374745-A-G, REVEL 0.15, CADD 22.00
- I4T (p.Ile4Thr), gnomAD 7-6374746-T-C, REVEL 0.46, CADD 26.40
- I4I (p.Ile4Ile), gnomAD 7-6374747-C-A, CADD 14.90
- K5S (p.Lys5Ser), gnomAD 7-6374747-CA-C, CADD 27.00
- K5E (p.Lys5Glu), gnomAD 7-6374748-A-G, REVEL 0.80, CADD 26.60
- K5* (p.Lys5Ter), gnomAD 7-6374748-A-T, CADD 40.00
- K5M (p.Lys5Met), gnomAD 7-6374749-A-T, REVEL 0.78, CADD 28.10
- K5R (p.Lys5Arg), gnomAD 7-6374749-A-G, REVEL 0.68, CADD 32.00
- K5N (p.Lys5Asn), gnomAD 7-6374750-G-T, REVEL 0.76, CADD 27.80
- K5K (p.Lys5Lys), rs2115177178, gnomAD 7-6374750-G-A, CADD 14.20
- C6G (p.Cys6Gly), Ensembl rs2115177182, REVEL 0.64, CADD 29.90
- p.Cys6dup, gnomAD 7-6374750-G-GTGC, CADD 22.30
- C6S (p.Cys6Ser), gnomAD 7-6374751-T-A, REVEL 0.69, CADD 27.70
- C6R (p.Cys6Arg), gnomAD 7-6374751-T-C, REVEL 0.71, CADD 29.70
- C6Y (p.Cys6Tyr), gnomAD 7-6374752-G-A, REVEL 0.72, CADD 32.00
- C6F (p.Cys6Phe), gnomAD 7-6374752-G-T, REVEL 0.56, CADD 26.80
- C6* (p.Cys6Ter), gnomAD 7-6374753-T-A, CADD 48.00
- C6W (p.Cys6Trp), gnomAD 7-6374753-T-G, REVEL 0.76, CADD 32.00
- C6C (p.Cys6Cys), gnomAD 7-6374753-T-C, CADD 18.10
- V7G (p.Val7Gly), gnomAD 7-6374749-AGT-A, CADD 32.00
- V7L (p.Val7Leu), gnomAD 7-6374754-G-T, REVEL 0.66, CADD 24.10
- V7M (p.Val7Met), gnomAD 7-6374754-G-A, REVEL 0.75, CADD 27.70
- V7E (p.Val7Glu), gnomAD 7-6374755-T-A, REVEL 0.84, CADD 29.30
- V7A (p.Val7Ala), gnomAD 7-6374755-T-C, REVEL 0.80, CADD 27.70
- V7V (p.Val7Val), gnomAD 7-6374756-G-T, CADD 13.60
- V8W (p.Val8Trp), gnomAD 7-6374755-TG-T, CADD 32.00
- V8L (p.Val8Leu), gnomAD 7-6374757-G-C, REVEL 0.28, CADD 23.70
- V8M (p.Val8Met), gnomAD 7-6374757-G-A, REVEL 0.59, CADD 26.40
- V8A (p.Val8Ala), gnomAD 7-6374758-T-C, REVEL 0.65, CADD 24.40
- V8E (p.Val8Glu), gnomAD 7-6374758-T-A, REVEL 0.75, CADD 32.00
- V8V (p.Val8Val), gnomAD 7-6374759-G-C, CADD 13.70
- V9E (p.Val9Glu), Ensembl rs2115177190, REVEL 0.79, CADD 28.40
- V9G (p.Val9Gly), Ensembl rs2115177190, REVEL 0.80, CADD 32.00
- V9del (p.Val9del), gnomAD 7-6374753-TGTG-T, CADD 21.90
- V9W (p.Val9Trp), gnomAD 7-6374758-TG-T, CADD 31.00
- V9M (p.Val9Met), gnomAD 7-6374760-G-A, REVEL 0.72, CADD 26.90
- V9L (p.Val9Leu), gnomAD 7-6374760-G-T, REVEL 0.51, CADD 23.80
- V9A (p.Val9Ala), gnomAD 7-6374761-T-C, REVEL 0.72, CADD 26.60
- V9V (p.Val9Val), gnomAD 7-6374762-G-T, CADD 12.30
- G10E (p.Gly10Glu), gnomAD 7-6374761-TG-T, CADD 24.80
- G10R (p.Gly10Arg), gnomAD 7-6374763-G-A, REVEL 0.77, CADD 29.00
- G10* (p.Gly10Ter), gnomAD 7-6374763-G-T, CADD 39.00
- G10V (p.Gly10Val), gnomAD 7-6374764-G-T, REVEL 0.79, CADD 25.50
- G10A (p.Gly10Ala), gnomAD 7-6374764-G-C, REVEL 0.76, CADD 25.20
- G10G (p.Gly10Gly), gnomAD 7-6374765-A-G, CADD 18.00
- D11E (p.Asp11Glu), cosmic curated COSV61822, Ensembl rs2115177198, REVEL 0.63, CADD 26.00
- D11G (p.Asp11Gly), Ensembl rs2115177195, REVEL 0.78, CADD 25.60
- D11H (p.Asp11His), NCI-TCGA Cosmic COSV6182, Variant assessed as somatic; moderate impact.
- D11N (p.Asp11Asn), cosmic curated COSV61825, Ensembl rs2115177193, REVEL 0.62, CADD 24.40
- D11Y (p.Asp11Tyr), gnomAD 7-6374766-G-T, REVEL 0.79, CADD 27.70
- D11V (p.Asp11Val), gnomAD 7-6374767-A-T, REVEL 0.78, CADD 27.60
- D11A (p.Asp11Ala), gnomAD 7-6374767-A-C, REVEL 0.80, CADD 24.20
- D11D (p.Asp11Asp), gnomAD 7-6374768-C-T, CADD 22.30
- G12* (p.Gly12Ter), gnomAD rs1183625015, CADD 40.00
- G12R (p.Gly12Arg), cosmic curated COSV61822, NCI-TCGA Cosmic COSV6182, REVEL 0.74, CADD 26.40, Variant assessed as somatic; moderate impact.
- G12V (p.Gly12Val), cosmic curated COSV61823, REVEL 0.71, CADD 33.00
- G12A (p.Gly12Ala), gnomAD 7-6374770-G-C, REVEL 0.65, CADD 29.10
- G12E (p.Gly12Glu), gnomAD 7-6374770-G-A, REVEL 0.70, CADD 33.00
- A13D (p.Ala13Asp), Ensembl rs2115193019, REVEL 0.65, CADD 26.90
- A13G (p.Ala13Gly), Ensembl rs2115193019
- A13P (p.Ala13Pro), Ensembl rs2115193010
- A13S (p.Ala13Ser), Ensembl rs2115193010, REVEL 0.47, CADD 29.70
- A13T (p.Ala13Thr), NCI-TCGA Cosmic COSV6182, cosmic curated COSV61822, Ensembl rs2115193010, Variant assessed as somatic; moderate impact.
- A13V (p.Ala13Val), Ensembl rs2115193019
- V14E (p.Val14Glu), NCI-TCGA Cosmic COSV6182, cosmic curated COSV61823, Ensembl rs2115193027, REVEL 0.85, CADD 27.30, Variant assessed as somatic; moderate impact.
- V14I (p.Val14Ile), rs2115193022, ClinGen CA366759845, ClinVar RCV003443399, Ensembl rs2115193022, AlphaMissense 0.86, MetaLR 0.78, Uncertain significance, not provided
- V14L (p.Val14Leu), cosmic curated COSV61824, Ensembl rs2115193022, Uncertain significance
- G15A (p.Gly15Ala), Ensembl rs2115193038
- G15D (p.Gly15Asp), Ensembl rs2115193038, REVEL 0.91, CADD 26.80
- G15R (p.Gly15Arg), Ensembl rs2115193034
- G15S (p.Gly15Ser), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, Variant assessed as somatic; moderate impact.
- G15G (p.Gly15Gly), gnomAD 7-6387221-T-C, CADD 11.70
- K16E (p.Lys16Glu), TOPMed rs1782948384, REVEL 0.89, CADD 25.00
- K16I (p.Lys16Ile), Ensembl rs2115193050
- K16N (p.Lys16Asn), Ensembl rs2115193053
- T17I (p.Thr17Ile), Ensembl rs1782948454, Uncertain significance
- T17P (p.Thr17Pro), Ensembl rs2115193057
- T17S (p.Thr17Ser), Ensembl rs2115193057, MetaLR 0.57, MetaSVM 0.07, Uncertain significance, Inborn genetic diseases
- T17A (p.Thr17Ala), gnomAD 7-6387225-A-G, REVEL 0.82, CADD 25.70
- C18* (p.Cys18Ter), TOPMed rs1243171237, gnomAD rs1243171237
- C18F (p.Cys18Phe), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, NCI-TCGA Cosmic COSV6182, Tier II - Potential, Germinoma
- C18S (p.Cys18Ser), cosmic curated COSV61823, Ensembl rs1554263326, Pathogenic, in MRD48
- C18W (p.Cys18Trp), TOPMed rs1243171237, gnomAD rs1243171237
- C18Y (p.Cys18Tyr), rs1554263326, ClinGen CA366759929, NCI-TCGA Cosmic COSV1006, NCI-TCGA Cosmic COSV6182, AlphaMissense 1.00, MetaLR 0.68, Pathogenic, not provided
- C18C (p.Cys18Cys), rs1243171237, gnomAD 7-6387230-C-T, CADD 10.10
- L19I (p.Leu19Ile), gnomAD rs1381712962
- L19Q (p.Leu19Gln), Ensembl rs2115193074, MetaLR 0.83, MetaSVM 0.99
- L19V (p.Leu19Val), gnomAD rs1381712962, REVEL 0.69, CADD 25.10
- L19L (p.Leu19Leu), rs1381712962, gnomAD 7-6387231-C-T, CADD 11.10
- L20P (p.Leu20Pro), 1000Genomes rs565555925, ExAC rs565555925, gnomAD rs565555925, REVEL 0.91, CADD 28.50
- L20Q (p.Leu20Gln), 1000Genomes rs565555925, ExAC rs565555925, gnomAD rs565555925, REVEL 0.89, CADD 27.50
- L20V (p.Leu20Val), Ensembl rs2115193085, MetaLR 0.63, MetaSVM 0.34
- L20L (p.Leu20Leu), rs2115193085, gnomAD 7-6387234-C-T, CADD 10.30
- L20M (p.Leu20Met), gnomAD 7-6387234-C-A, REVEL 0.63, CADD 24.70
- I21F (p.Ile21Phe), Ensembl rs2115193099
- I21M (p.Ile21Met), TOPMed rs1177487354, gnomAD rs1177487354
- I21N (p.Ile21Asn), cosmic curated COSV61822, Ensembl rs2115193102
- I21S (p.Ile21Ser), cosmic curated COSV10590
- I21V (p.Ile21Val), cosmic curated COSV61824, MetaLR 0.46, MetaSVM -0.25
- I21I (p.Ile21Ile), rs1177487354, gnomAD 7-6387239-C-T, CADD 11.40
- S22C (p.Ser22Cys), Ensembl rs2115193110
- S22G (p.Ser22Gly), Ensembl rs2115193110
- S22N (p.Ser22Asn), cosmic curated COSV61822
- S22R (p.Ser22Arg), Ensembl rs2115193117, MetaLR 0.27, MetaSVM -0.54
- S22S (p.Ser22Ser), gnomAD 7-6387242-T-C, CADD 9.62
- Y23F (p.Tyr23Phe), Ensembl rs2115193123, MetaLR 0.43, MetaSVM -0.13
- Y23Y (p.Tyr23Tyr), rs761870622, gnomAD 7-6387245-C-T, CADD 1.47
- T24A (p.Thr24Ala), Ensembl rs2115193128
- T24R (p.Thr24Arg), Ensembl rs2115193133
- T24S (p.Thr24Ser), Ensembl rs2115193128, MetaLR 0.70, MetaSVM 0.50
- T24T (p.Thr24Thr), rs1583262597, gnomAD 7-6387248-A-G, CADD 1.74
- T25A (p.Thr25Ala), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, Variant assessed as somatic; moderate impact.
- T25I (p.Thr25Ile), Ensembl rs2115193143
- T25N (p.Thr25Asn), Ensembl rs2115193143, REVEL 0.48, CADD 23.40
- T25S (p.Thr25Ser), rs2115193140, ClinGen CA366760032, cosmic curated COSV10967, ClinVar RCV002462692, AlphaMissense 0.65, MetaLR 0.37, Uncertain significance, not provided
- T25T (p.Thr25Thr), rs139010955, gnomAD 7-6387251-C-G, CADD 10.70
- N26D (p.Asn26Asp), rs2115193158, NCI-TCGA Cosmic COSV6182, cosmic curated COSV61822, UniProt VAR 014540, AlphaMissense 0.90, MetaLR 0.66, Variant assessed as somatic; moderate impact.
- N26I (p.Asn26Ile), Ensembl rs1782949423, Likely pathogenic
- N26K (p.Asn26Lys), Ensembl rs2115193165
- N26S (p.Asn26Ser), rs1782949423, ClinGen CA366760056, ClinVar RCV001267613, ClinVar RCV001824437, REVEL 0.54, CADD 25.40, Pathogenic, not provided; Inborn genetic diseases
- N26Y (p.Asn26Tyr), Ensembl rs2115193158, MetaLR 0.66, MetaSVM 0.56
- A27E (p.Ala27Glu), Ensembl rs2115193175, REVEL 0.54, CADD 23.60
- A27G (p.Ala27Gly), Ensembl rs2115193175
- A27P (p.Ala27Pro), Ensembl rs2115193169
- A27T (p.Ala27Thr), Ensembl rs2115193169, MetaLR 0.29, MetaSVM -0.61
- A27V (p.Ala27Val), Ensembl rs2115193175, REVEL 0.35, CADD 24.00
- A27A (p.Ala27Ala), rs1357653249, gnomAD 7-6387257-A-G, CADD 2.87
- F28L (p.Phe28Leu), rs2115193183, UniProt VAR 014541, Ensembl rs2115193183, AlphaMissense 1.00, MetaLR 0.79
- F28C (p.Phe28Cys), gnomAD 7-6387259-T-G, REVEL 0.82, CADD 29.50
- P29A (p.Pro29Ala), NCI-TCGA Cosmic COSV6182, Ensembl rs1057519874, Variant assessed as somatic; moderate impact.
- P29F (p.Pro29Phe), cosmic curated COSV61824
- P29H (p.Pro29His), cosmic curated COSV10742, NCI-TCGA Cosmic COSV6182, Ensembl rs1057519948, Variant assessed as somatic; moderate impact.
- P29L (p.Pro29Leu), rs1057519948, NCI-TCGA Cosmic COSV6182, cosmic curated COSV61821, AlphaMissense 1.00, MetaLR 0.73, Likely oncogenic, Neoplasm
- P29R (p.Pro29Arg), cosmic curated COSV61824, Ensembl rs1057519948
- P29S (p.Pro29Ser), cosmic curated COSV61821, Ensembl rs1057519874
- P29T (p.Pro29Thr), cosmic curated COSV61823, Ensembl rs1057519874, MetaLR 0.62, MetaSVM 0.23
- P29P (p.Pro29Pro), gnomAD 7-6387263-T-C, CADD 7.62
- G30A (p.Gly30Ala), Ensembl rs2115193199
- G30E (p.Gly30Glu), cosmic curated COSV61824, Ensembl rs2115193199
- G30R (p.Gly30Arg), Ensembl rs2115193197
- G30V (p.Gly30Val), Ensembl rs2115193199, MetaLR 0.52, MetaSVM 0.05
- G30* (p.Gly30Ter), gnomAD 7-6387264-G-T, CADD 47.00
- G30G (p.Gly30Gly), rs2115193205, gnomAD 7-6387266-A-G, CADD 14.40
- E31D (p.Glu31Asp), cosmic curated COSV61822, gnomAD rs949165072, NCI-TCGA Cosmic COSV6182, cosmic curated COSV61821, Variant assessed as somatic; moderate impact.
- E31K (p.Glu31Lys), Ensembl rs2115193206
- E31Q (p.Glu31Gln), Ensembl rs2115193206
- E31V (p.Glu31Val), rs2534020732, ClinGen CA366760122, ClinVar RCV003154324, Uncertain significance, not provided
- E31E (p.Glu31Glu), rs949165072, gnomAD 7-6387269-A-G, CADD 2.69
- Y32* (p.Tyr32Ter), gnomAD rs1248078503
- Y32N (p.Tyr32Asn), Ensembl rs2115193219, MetaLR 0.56, MetaSVM 0.14
- Y32H (p.Tyr32His), gnomAD 7-6387270-T-C, REVEL 0.82, CADD 27.40
- Y32Y (p.Tyr32Tyr), rs1248078503, gnomAD 7-6387272-T-C, CADD 0.88
- I33F (p.Ile33Phe), NCI-TCGA Cosmic COSV6182, cosmic curated COSV61824, Ensembl rs2115193223, MetaLR 0.62, MetaSVM 0.35, Variant assessed as somatic; moderate impact.
- I33M (p.Ile33Met), TOPMed rs1240617392, gnomAD rs1240617392, REVEL 0.60, CADD 22.80
- I33I (p.Ile33Ile), rs1240617392, gnomAD 7-6387275-C-T, CADD 8.36
- P34A (p.Pro34Ala), Ensembl rs2115193228
- P34H (p.Pro34His), NCI-TCGA Cosmic COSV6182, cosmic curated COSV61822, Ensembl rs1782950049, REVEL 0.73, CADD 25.60, Variant assessed as somatic; moderate impact.
- P34L (p.Pro34Leu), cosmic curated COSV10526, MetaLR 0.74, MetaSVM 0.68
- P34R (p.Pro34Arg), NCI-TCGA Cosmic COSV6182, cosmic curated COSV61823, Ensembl rs1782950049, REVEL 0.81, CADD 25.40, Variant assessed as somatic; moderate impact.
- P34S (p.Pro34Ser), NCI-TCGA Cosmic COSV6182, cosmic curated COSV61823, Ensembl rs2115193228, REVEL 0.70, CADD 25.00, Variant assessed as somatic; moderate impact.
- P34T (p.Pro34Thr), Ensembl rs2115193228, REVEL 0.76, CADD 24.70
Public RAC1 analysis runs
- RAC1 analysis run — RAC1 (508 variants) — completed 2026-08-21